26 September 2023
News
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
Results suggest SSRIs enhance the efficacy of SPL026 when administered to MDD patients on a…
News & Insights
Check out the latest company media, insights, and press releases. Delve into all the content on specific topic areas such as Company Financials.
28 August 2023
News
Cybin to Acquire Small Pharma Inc.
Cybin to acquire Small Pharma creating an international clinical-stage leader in novel psychedelic therapeutics.
27 July 2023
News
Small Pharma Reports Fiscal First Quarter 2024 Highlights
Financial highlights and recent business and R&D highlights.
5 July 2023
News
Small Pharma Announces Management Team Change
Mr. Peter Rands, co-founder and former CEO, has left his positions as an executive officer…
5 July 2023
News
Small Pharma Announces SPL028 R&D Strategy Update
Preliminary findings from ongoing Phase I trial of SPL028 indicate potential for a unique therapeutic…
28 June 2023
News
Small Pharma Reports Financial Results for Fiscal Year End and Recent Business Highlights
Multiple clinical milestones achieved with operational efficiencies underway.
25 May 2023
News
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
5 new patent grants with 3 expected upcoming patent grants in May.
4 May 2023
Insights
May 2023 Latest News Round-up
A highlight of recent news and events across April and May.
5 April 2023
Insights
April 2023 Company Update
A highlight of recent news and events so far.
4 April 2023
News
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
Patients who achieved remission within three months sustained remission to six months.